New Drugs for the Treatment of Tuberculosis

Elisa H. Ignatius, Kelly E. Dooley

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Tuberculosis (TB) has now surpassed HIV as the leading infectious cause of death, and treatment success rates are declining. Multidrug-resistant TB, extensively drug-resistant TB, and even totally drug-resistant TB threaten to further destabilize disease control efforts. The second wave in TB drug development, which includes the diarylquinoline, bedaquiline, and the nitroimidazoles delamanid and pretomanid, may offer options for simpler, shorter, and potentially all-oral regimens to treat drug-resistant TB. The “third wave” of TB drug development includes numerous promising compounds, including less toxic versions of older drug classes and candidates with novel mechanisms of action.

Original languageEnglish (US)
Pages (from-to)811-827
Number of pages17
JournalClinics in Chest Medicine
Issue number4
StatePublished - Dec 2019


  • Bedaquiline
  • Delamanid
  • New drugs
  • Pharmacology
  • Pretomanid
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'New Drugs for the Treatment of Tuberculosis'. Together they form a unique fingerprint.

Cite this